Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma
Status:
Withdrawn
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
This trial explores the immunologic effects of vemurafenib (BRAF inhibitor) and cobimetinib
(MEK inhibitor), administered alone and in combination, to patients with advanced BRAF
V600E/K mutant melanoma.
Phase:
Phase 3
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins